Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Novo Nordisk has abruptly terminated its collaboration with Hims & Hers, accusing the telehealth company of failing to adhere to laws regarding compounded weight loss drug sales, particularly following the FDA's declaration that the Wegovy shortage is over. This swift dissolution of a partnership launched just in April led to a 35% plunge in Hims & Hers shares. The move underscores the escalating regulatory and market tension between branded pharmaceutical manufacturers and telehealth platforms leveraging compounded GLP-1RAs, as the FDA mandates cessation of mass compounded production post-shortage.

Analysis

The abrupt termination of the Novo Nordisk (NVO) and Hims & Hers (HIMS) collaboration, initiated only in April, signals a significant escalation in the conflict between branded pharmaceutical manufacturers and telehealth platforms over compounded drugs. The immediate market reaction was a 35% plunge in HIMS shares, reflecting acute investor concern over the sustainability of its business model. The dispute is rooted in the FDA's declaration in April that the shortage of Wegovy, NVO's blockbuster GLP-1RA, was over, thereby removing the primary legal justification for the mass production of compounded alternatives. Novo Nordisk alleges Hims & Hers failed to adhere to the subsequent FDA mandate to cease compounded production by May 22, accusing the telehealth firm of using the "false guise of 'personalisation'" and engaging in "deceptive marketing." This move represents a decisive strategy by NVO to protect its flagship product's revenue from the compounded market, a sector that had previously forced the drugmaker to slash its 2025 outlook. Hims & Hers' counter-accusation of "anticompetitive demands" and its stated intent to continue offering tailored formulations places it in direct opposition to both its former partner and regulatory directives, introducing substantial legal and operational risk for a key segment of its high-growth revenue stream.

Key Decisions for Investors

• Investors should treat the 35% share price drop in Hims & Hers as a reflection of significant legal and regulatory risk that directly threatens the sustainability of its compounded drug revenue, warranting extreme caution.
• Novo Nordisk's decisive action to protect its Wegovy franchise is a strong positive signal for the stock, as it mitigates revenue erosion from the gray market and reinforces its alignment with FDA directives.
• This conflict serves as a critical warning for the broader telehealth sector; positions in companies reliant on compounded drug sales should be re-evaluated for similar vulnerabilities to regulatory enforcement and manufacturer legal action.